Literature DB >> 17588764

In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias.

Rosario Sánchez-Pernaute1, Bruce G Jenkins, Ji-Kyung Choi, Yin-Ching Iris Chen, Ole Isacson.   

Abstract

A growing body of evidence indicates a role for D(3) receptors in l-DOPA-induced dyskinesias. This involvement could be amenable to non-invasive in vivo analysis using functional neuroimaging. With this goal, we examined the hemodynamic response to the dopamine D(3)-preferring agonist 7-hydroxy-N,N-di-n-propyl-2 aminotetralin (7-OHDPAT) in naïve, parkinsonian and l-DOPA-treated, dyskinetic rodents and primates using pharmacological MRI (phMRI) and relative cerebral blood volume (rCBV) mapping. Administration of 7-OHDPAT induced minor negative changes of rCBV in the basal ganglia in naïve and parkinsonian animals. Remarkably, the hemodynamic response was reversed (increased rCBV) in the striatum of parkinsonian animals rendered dyskinetic by repeated l-DOPA treatment. Such increase in rCBV is consistent with D(1) receptor-like signaling occurring in response to D(3) stimulation, demonstrates a dysregulation of dopamine receptor function in dyskinesia and provides a potentially novel means for the characterization and treatment of l-DOPA-induced dyskinesia in patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17588764      PMCID: PMC2674779          DOI: 10.1016/j.nbd.2007.04.016

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  44 in total

1.  Calcium transients in astrocyte endfeet cause cerebrovascular constrictions.

Authors:  Sean J Mulligan; Brian A MacVicar
Journal:  Nature       Date:  2004-09-09       Impact factor: 49.962

Review 2.  Levodopa in the treatment of Parkinson's disease: current controversies.

Authors:  C Warren Olanow; Yves Agid; Yoshi Mizuno; Alberto Albanese; Ubaldo Bonuccelli; U Bonucelli; Philip Damier; Justo De Yebenes; Oscar Gershanik; Mark Guttman; F Grandas; Mark Hallett; Ole Hornykiewicz; Peter Jenner; R Katzenschlager; William J Langston; Peter LeWitt; Eldad Melamed; M A Mena; P P Michel; Catherine Mytilineou; Jose A Obeso; Werner Poewe; Niall Quinn; R Raisman-Vozari; Ali H Rajput; Olivier Rascol; Christina Sampaio; Fabrizio Stocchi
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

Review 3.  Coactivation of D1 and D2 dopamine receptors: in marriage, a case of his, hers, and theirs.

Authors:  Alexia Pollack
Journal:  Sci STKE       Date:  2004-10-19

4.  A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.

Authors:  Kevin J Black; Tamara Hershey; Jonathan M Koller; Tom O Videen; Mark A Mintun; Joseph L Price; Joel S Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

5.  Transplanted dopamine neurons derived from primate ES cells preferentially innervate DARPP-32 striatal progenitors within the graft.

Authors:  Daniela Ferrari; Rosario Sanchez-Pernaute; Hyojin Lee; Lorenz Studer; Ole Isacson
Journal:  Eur J Neurosci       Date:  2006-10       Impact factor: 3.386

6.  Altered behavioral response to dopamine D3 receptor agonists 7-OH-DPAT and PD 128907 following repetitive amphetamine administration.

Authors:  Neil M Richtand; Jeffrey A Welge; Beth Levant; Aaron D Logue; Scott Hayes; Laurel M Pritchard; Thomas D Geracioti; Lique M Coolen; S Paul Berger
Journal:  Neuropsychopharmacology       Date:  2003-04-16       Impact factor: 7.853

7.  Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.

Authors:  Erwan Bézard; Sandrine Ferry; Ulrich Mach; Holger Stark; Ludovic Leriche; Thomas Boraud; Christian Gross; Pierre Sokoloff
Journal:  Nat Med       Date:  2003-05-12       Impact factor: 53.440

8.  Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Authors:  Junchao Tong; Paul S Fitzmaurice; Lee Cyn Ang; Yoshiaki Furukawa; Mark Guttman; Stephen J Kish
Journal:  Ann Neurol       Date:  2004-01       Impact factor: 10.422

Review 9.  Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease.

Authors:  Olivier Guillin; Nathalie Griffon; Erwan Bezard; Ludovic Leriche; Jorge Diaz; Christian Gross; Pierre Sokoloff
Journal:  Eur J Pharmacol       Date:  2003-11-07       Impact factor: 4.432

10.  Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.

Authors:  Bruce G Jenkins; Rosario Sanchez-Pernaute; Anna-Liisa Brownell; Yin-Ching Iris Chen; Ole Isacson
Journal:  J Neurosci       Date:  2004-10-27       Impact factor: 6.709

View more
  24 in total

1.  Quantitative pharmacologic MRI: mapping the cerebral blood volume response to cocaine in dopamine transporter knockout mice.

Authors:  Teodora-Adriana Perles-Barbacaru; Daniel Procissi; Andrey V Demyanenko; F Scott Hall; George R Uhl; Russell E Jacobs
Journal:  Neuroimage       Date:  2010-12-23       Impact factor: 6.556

2.  Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.

Authors:  Dennis A Brown; Manoj Mishra; Suhong Zhang; Swati Biswas; Ingrid Parrington; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  Bioorg Med Chem       Date:  2009-04-19       Impact factor: 3.641

3.  Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay Riddle; Suzy A Griffin; Peter Grundt; Amy Hauck Newman; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

4.  Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay R Riddle; Suzy A Griffin; Wenhua Chu; Suwanna Vangveravong; Janet Neisewander; Robert H Mach; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

5.  Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates.

Authors:  R Sanchez-Pernaute; J-Q Wang; D Kuruppu; L Cao; W Tueckmantel; A Kozikowski; O Isacson; A-L Brownell
Journal:  Neuroimage       Date:  2008-04-20       Impact factor: 6.556

6.  Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists.

Authors:  Ji-Kyung Choi; Joseph B Mandeville; Y Iris Chen; Peter Grundt; Susanta K Sarkar; Amy H Newman; Bruce G Jenkins
Journal:  Psychopharmacology (Berl)       Date:  2010-07-14       Impact factor: 4.530

7.  Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.

Authors:  Claudia Rangel-Barajas; Maninder Malik; Michelle Taylor; Kim A Neve; Robert H Mach; Robert R Luedtke
Journal:  J Neurochem       Date:  2014-08-19       Impact factor: 5.372

Review 8.  Human embryonic stem cells: a potential source of transplantable neural progenitor cells.

Authors:  Daniel J Guillaume; Su-Chun Zhang
Journal:  Neurosurg Focus       Date:  2008       Impact factor: 4.047

Review 9.  A key role of the basal ganglia in pain and analgesia--insights gained through human functional imaging.

Authors:  David Borsook; Jaymin Upadhyay; Eric H Chudler; Lino Becerra
Journal:  Mol Pain       Date:  2010-05-13       Impact factor: 3.395

10.  Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism.

Authors:  Riccardo Viaro; Rosario Sanchez-Pernaute; Matteo Marti; Claudio Trapella; Ole Isacson; Michele Morari
Journal:  Neurobiol Dis       Date:  2008-03-08       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.